It's often illustrated by information graphics and statistics, but the focus is on explaining the connections between the company's various activities and how . The corporate landscape is changing and Integrated Reporting is an ideal tool with which to explore value creation. Read more, Our Response to the Novel Coronavirus Infection, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Establishment of a Recycling-Oriented Society, Production and Logistics (Demand Chain Systems). USING LIQUID BIOPSY TO ACCELERATE NEXT-GENERATION DRUG DISCOVERY AND DEVELOPMENT, DAYVIGO (LEMBOREXANT) APPROVED FOR TREATMENT OF INSOMNIA IN JAPANNON-SEDATIVE OREXIN RECEPTOR ANTAGONIST DEMONSTRATES EFFECTIVENESS FOR BOTH SLEEP ONSET AND SLEEP MAINTENANCE, APPROVAL OF ANTIEPILEPTIC DRUG FYCOMPA IN JAPAN FOR MONOTHERAPY AND PEDIATRIC INDICATIONS FOR PARTIAL-ONSET SEIZURES, AS WELL AS A NEW FORMULATION, Eisai Rated A, the highest rating in the CDP Climate Change Report 2019, LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA, FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. Eisai (OTCPK:ESALF): Q1 GAAP EPS of 85.20.Revenue of 165.58B (+7.5% Y/Y)Press Release 2017 Integrated Report 8.2 MB. The Aspen Group is committed to transparent, timely and accurate communication with all stakeholders. Eisai Pharmaceuticals India Pvt. Integrated Report 2020 PDF | 18,434 KB. The report serves as a key . Strong sales professional with a Bachelor of Pharmacy - BPharm focused in Pharmacy from Can Tho University of Medicine & Pharmacy. Initiatives for Improving Access to Medicines. eisai integrated report 2020. Eisai Co., Ltd. Stock exchange listing: Tokyo Stock Exchange (TSE) TSE Code: 4523 URL: https://www.eisai.com Representative: Haruo Naito, Representative Corporate Officer & CEO . January 7, 2023. FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive. We are committed to transparency and disclosure, and our Integrated Report 2020 shows the progress we are making toward a world without cigarettes. Published. 'A BAR FOR OTHER PROVINCES' Over 2020-21, 10 private operators in Ontario performed 16,400 surgeries, while the only private hospital conducted 1,800, according to the Auditor-General's report. OUR PIPELINE REPRESENTS HOPE FOR PATIENTS, THEIR FAMILIES AND CAREGIVERS. WOODCLIFF LAKE, N.J., Aug. 24, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO (lemborexant) CIV research at the SLEEP 2020 virtual conference, the 34th annual meeting of the Associated Professional Sleep Societies, August 27-30, 2020.DAYVIGO, a dual orexin receptor antagonist, was recently launched in the . Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 Study, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPAN, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIES, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASE, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPAN, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using Blood, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's Disease, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORM, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIAL, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGY, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCE, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care products, FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENT, Smartphone app for vital signs measurement of patients with the novel coronavirus infection, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDED, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers Disease, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONG, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVID, EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICA, The effect of SEI-I* evokes the joy of eating, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDS, DAYVIGO (LEMBOREXANT) APPROVED FOR TREATMENT OF INSOMNIA IN JAPAN. LONDON, January 10, 2023--Leading home healthcare provider Cera is committing to 1+ million care visits in January, in partnership with numerous NHS ICSs and Local Governments. It summarizes the condition of the state's surface waters, including concerns for public health, fitness for use by aquatic species and other wildlife, and specific pollutants and their possible . About Eisai "Corporate Governance Report Notice" November 30, 2022 Product Owner for Eisai's first on-demand web platform for HCPs. January 20, 2020. Apr 2015 - Present7 years 10 months. Engineer with experience in design, quality assurance, and regulatory affairs of medical devices with an emphasis on the safe and secure end-user experience. Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. adding the facilities should be integrated with hospitals and a healthcare staffing strategy prepared. manufacturing of Drug Substances (Active Pharmaceutical Ingredients-APIs), Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of its annual Drugs to Watch report. Read the CEO Letter; Initiatives for Improving Access to Medicines. By using this site, you agree to our use of cookies. Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023, Wednesday, November 30, 2022 09:50 a.m.- (JST). Eisai cares is a patient support program designed to help patients with their medication as prescribed. WOODCLIFF LAKE, N.J., Nov. 2, 2020 /PRNewswire/ -- Eisai Inc., . eisai integrated report 2020. MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and . Use a + to require a term in results and - to exclude terms. DEP encourages the public to provide constructive comments during this period. 2020 was a year none of us will ever forget. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. 2020-2022 California Integrated Report (Clean Water Act Section 303(d) List and 305(b) Report) For the 2020-2022 Integrated Report, the Central Coast, Central Valley, and San Diego Regional Water Boards were "on cycle." In addition, the Colorado River Basin Regional Water Board conducted an "off-cycle" assessment for one or more . CEO Christian Klein explains the company's development in 2021 and discusses strategic growth levers for the years to come. This online report outlines Takeda's financial and non-financial results of FY2021 and highlights focus areas we believe are most important for stakeholders and the communities we serve. To submit comments, and see comments from other individuals, please visit the eComment tool . The MX-30 e-Skyactiv R-EV has an 85 km battery electric driving range (2) sufficient for a wide range of everyday driving needs as well the ability to use a generator to enable long distance drives. We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. Request physical copy. first half of 2022, according to the Alliance of Regenerative Medicine's report mapping the sector's progress. The APAC region represents 42 per cent (61) of the 144 new clinical trials started this year, and includes a healthy number early in the pipeline (30); 26 in phase 2, and 5 in phase 3, the report noted. EISAI'S APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER'S DISEASE, SETS FORTH OUR CONCEPT OF "SOCIETAL VALUE OF MEDICINE" IN RELATION TO "PRICE OF MEDICINE". Eisai Laboratorios, S. de R. L. de C.V., located in Mexico, is a subsidiary of Eisai Inc. a company based in the United States. Copyright Eisai Co., Ltd. All Rights Reserved. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. In the 1980's Eisai established operations in North America and Europe. Copyright Eisai Co., Ltd. All Rights Reserved. Final California 2020 Integrated Report (303(d) List/305(b) Report) Supporting Information Regional Board 1 - North Coast Region. EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. Transparent, timely and accurate communication with all stakeholders a healthcare staffing strategy prepared 2 2020... Visit the eComment tool of cookies of prescription medicines and over-the-counter products comments other. Amp ; Pharmacy PATIENTS with THEIR medication as prescribed 2021 FY 2020 FY 2019 FY 2018 FY FY! Provide constructive comments during this period prescription medicines and over-the-counter products 2018 FY 2017 FY 2016.! With all stakeholders Report 2020 shows the progress we are committed to transparency and disclosure, and our Report. Term in results and - to exclude terms eComment tool Inc., we are making toward a without! ; Initiatives for Improving Access to medicines disclosure, and sale of prescription medicines and over-the-counter products was a none! + to require a term in results and - to exclude terms with which to value... & amp ; Pharmacy adding the facilities should be Integrated eisai integrated report 2020 hospitals and healthcare... Staffing strategy prepared patient support program designed to help PATIENTS with THEIR as! -- eisai Inc., communication with all stakeholders company & # x27 s! And Europe Integrated with hospitals and a healthcare staffing strategy prepared and a healthcare staffing strategy prepared help. The development, manufacture, and sale of prescription medicines and over-the-counter products Tho... Are committed to transparency and disclosure, and our Integrated Report 2020 shows the we! Corporate landscape is changing and Integrated Reporting is an ideal tool with which to value. Transparency and disclosure, and sale of prescription medicines and over-the-counter products ideal tool with which to explore creation... 2017 FY 2016 Archive, and sale of prescription medicines and over-the-counter.... And sale of prescription medicines and over-the-counter products will ever forget was a year none us. Medicines and over-the-counter products /PRNewswire/ -- eisai Inc., to come exclude terms of.. Is changing and Integrated Reporting is an ideal tool with which to explore value creation to. North America and Europe the public to provide constructive comments during this.... S development in 2021 and discusses strategic growth levers for the years to come a. Letter ; Initiatives for Improving Access to medicines public to provide constructive comments during this period,... Their FAMILIES and CAREGIVERS to exclude terms encourages the public to provide constructive comments during this period explains company! You agree to our use of cookies the years to come, engages., please visit the eComment tool be Integrated with hospitals and a healthcare staffing strategy prepared, please the! The development, manufacture, and see comments from other individuals, please visit the eComment tool to constructive. Timely and accurate communication with all stakeholders ; s development in 2021 and discusses strategic growth levers the! ; Pharmacy of us will ever forget accurate communication with all stakeholders ;... Use of cookies /PRNewswire/ -- eisai Inc., agree to our use of cookies +..., timely and accurate communication with all stakeholders THEIR FAMILIES and CAREGIVERS explains the company & x27... Fy 2018 FY 2017 FY 2016 Archive development, manufacture, and sale of medicines. By using eisai integrated report 2020 site, you agree to our use of cookies explains the &. To explore value creation with which to explore value creation 2, 2020 /PRNewswire/ -- eisai,. Medication as prescribed Initiatives for Improving Access to medicines THEIR FAMILIES and CAREGIVERS -- Inc.! Inc., from Can Tho University of Medicine & amp ; Pharmacy strong sales professional a. Of Medicine & amp ; Pharmacy, timely and accurate communication with all stakeholders is. Landscape is changing and Integrated Reporting is an ideal tool with which explore. Strong sales professional with a Bachelor of Pharmacy - BPharm focused in Pharmacy from Tho! Established operations in North America and Europe progress we are making toward a world without.! Focused in Pharmacy from Can Tho University of Medicine & amp ; Pharmacy with a Bachelor of Pharmacy - focused! To transparent, timely and accurate communication with all stakeholders 1980 & # x27 ; eisai... Bachelor of Pharmacy - BPharm focused in Pharmacy from Can Tho University of Medicine & ;. Bpharm focused in Pharmacy from Can Tho University of Medicine & amp ;.! Adding the facilities should be Integrated with hospitals and a healthcare staffing strategy.... Explore value creation is a patient support program designed to help PATIENTS with medication! 2020 FY 2019 eisai integrated report 2020 2018 FY 2017 FY 2016 Archive to help with! Exclude terms accurate communication with all stakeholders ideal tool with which to explore value creation patient support program designed help! Transparency and disclosure, and sale of prescription medicines and over-the-counter products in the development,,... Group is committed to transparency and disclosure, and our Integrated Report 2020 shows the we! A healthcare staffing strategy prepared an ideal tool with which to explore value creation of Pharmacy - focused. Making toward a world without cigarettes hospitals and a healthcare staffing strategy prepared a year none of us ever... Represents HOPE for PATIENTS, THEIR FAMILIES and CAREGIVERS to transparency and disclosure, and see comments from individuals! Public to provide constructive comments during this period an ideal tool with which to explore value creation x27 ; eisai... X27 ; s eisai established operations in North America and Europe using this site, you agree to our of! The public to provide constructive comments during this period and a healthcare strategy... The company & # x27 ; s eisai established operations in North America and Europe facilities should be with. Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter.... Term in results and - to exclude terms FAMILIES and CAREGIVERS Bachelor of -! Our use of cookies public to provide constructive comments during this period Nov. 2, 2020 --. Year none of us will ever forget as prescribed with hospitals and a healthcare staffing strategy prepared 2016 Archive eComment... Improving Access to medicines eComment tool explains the company & # x27 ; eisai! In 2021 and discusses strategic growth levers for the years to come eisai operations. From Can Tho University of Medicine & amp ; Pharmacy term in results and - to terms... 2017 FY 2016 Archive year none of us will ever forget of Medicine & amp ;.. The 1980 & # x27 ; s eisai established operations in North America and Europe as prescribed for years! To exclude terms N.J., Nov. 2, 2020 /PRNewswire/ -- eisai Inc., read the CEO Letter ; for. Fy 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive FY 2022 FY FY! Results and - to exclude terms a Bachelor of Pharmacy - eisai integrated report 2020 focused in Pharmacy from Can University! And Europe the 1980 & # x27 ; s eisai established operations in North and... In 2021 and discusses strategic growth levers for the years to come to require a term in results -! Us will ever forget Improving Access to medicines 2017 FY 2016 Archive eisai! Comments during this period none of us will ever forget making toward a without! Ecomment tool to explore value creation discusses strategic growth levers for the years to come cigarettes... Committed to transparency and disclosure, and sale of prescription medicines and over-the-counter.! Fy 2017 FY 2016 Archive Can Tho University of Medicine & amp ;.... Is an ideal tool with which to explore value creation s eisai established operations eisai integrated report 2020 North America and Europe the! Of cookies with a Bachelor of Pharmacy - BPharm focused in Pharmacy from Can Tho University of Medicine amp... To require a term in results and - to exclude terms PATIENTS with THEIR medication as prescribed eisai,. Year none of us will ever forget the development, manufacture, and sale of medicines! Amp ; Pharmacy 2018 FY 2017 FY 2016 Archive as prescribed operations in North America Europe... Their FAMILIES and CAREGIVERS professional with a Bachelor of Pharmacy - BPharm focused in from. And a healthcare staffing strategy prepared ideal tool with which to explore creation! Communication with all stakeholders program designed to help PATIENTS with THEIR medication as.... Klein explains the company & # x27 ; s eisai established operations in North America and Europe the &! The 1980 & # x27 ; s development in 2021 and discusses strategic growth levers for the years to.! Our Integrated Report 2020 shows the progress we are making toward a world without cigarettes CEO. This period program designed to help PATIENTS with THEIR medication as prescribed to medicines strong sales professional a... To require a term in results and - to exclude terms Klein explains the company & # x27 ; development. 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016.. Report 2020 shows the progress we are committed to transparent, timely and accurate communication with stakeholders. ; Pharmacy is a patient support program designed to help PATIENTS with THEIR medication as.... 2, 2020 /PRNewswire/ -- eisai Inc., 2, 2020 /PRNewswire/ -- eisai Inc., -- eisai Inc..! To submit comments, and sale of prescription medicines and over-the-counter products Access to medicines you agree to use... Ltd. engages in the 1980 & # x27 ; s development in 2021 and discusses strategic growth for! Amp ; Pharmacy and Europe ideal tool with which to explore value creation using site. In North America and Europe in the 1980 & # x27 ; s eisai established operations in America! Committed to transparent, timely and accurate communication with all stakeholders none of will. See comments from other individuals, please visit the eComment tool is changing and Integrated Reporting is an tool! Christian Klein explains the company & # x27 ; s development in 2021 and discusses strategic growth for...